---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-096921"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:40:58.936980+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Regeneron expects Q3 2025 pre-tax IPR&D charge of ~$83M, reducing EPS by $0.68

## Summary
- Pre-tax acquired IPR&D charge of ~$83M for Q3 2025, primarily from $80M upfront to Hansoh Pharma.
- Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.68 per share.
- Preliminary results subject to financial statement closing procedures and may change.
- Regeneron does not forecast such IPR&D charges due to uncertainty in timing and magnitude.

## SEC filing metadata
- accession: 0001104659-25-096921
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/0001104659-25-096921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/tm2528010d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-096921
- JSON: https://secwatch.observer/filing/0001104659-25-096921.json
- Plain text: https://secwatch.observer/filing/0001104659-25-096921.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.